ZIA BC 011367 (ZIA) | |||
---|---|---|---|
Title | A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kreisl, Teri | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $14,799 | Project Dates | 10/01/2010 - N/A |
Fiscal Year | 2011 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) |
Brain (100.0%) Nervous System (100.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
Objectives: 1. To evaluate the anti-glioma activity of sunitinib in patients with recurrent malignant gliomas who are either naive or resistant to prior bevacizumab therapy. Eligibility: Patients with recurrent malignant glioma are eligible for this study. Design: 1. This is a phase II study with a target enrollment of 64 patients who have not progressed on prior treatment with anti-VEGF therapy, and 64 patients who have progressed on prior bevacizumab therapy. 2. Sunitinib will be self-administered orally at 37.5 mg daily, with dose adjustments allowed for toxicity and concomitant drug interactions. 3. The primary endpoint is six-month progression free survival for both arms of the study. |